Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives

Schizophrenia Research

Volumn 103, Issue 1-3, 2008, Pages 83-93

  Carrizo, Edgardo ^a   Fernández, Virginia ^a   Quintero, Jesús ^a   Connell, Lissette ^a   Rodríguez, Zulay ^a   Mosquera, Mônica ^b   Acosta, Arnaldo ^c   Baptista, Trino ^d  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b University Psychiatric Hospital   (Venezuela)

^c Universidad Nacional Experimental Francisco de Miranda   (Venezuela)

^d Universidad De Los Andes Facultad de Medicina   (Venezuela)

Author keywords

Antithrombin III; C reactive protein; Clozapine; Fibrinogen; Leptin; Olanzapine; Plasminogen activator inhibitor; Typical antipsychotics

Indexed keywords

ANTITHROMBIN III; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOZAPINE; FIBRINOGEN; HALOPERIDOL; LEPTIN; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIFLUOPERAZINE;

ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; FEMALE; HABIT; HUMAN; INFLAMMATION; LIFESTYLE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; RELATIVE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ANTITHROMBIN III; BENZODIAZEPINES; BODY MASS INDEX; C-REACTIVE PROTEIN; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION MEDIATORS; LEPTIN; LIFE STYLE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SCHIZOPHRENIA; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 47349088594     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.03.004     Document Type: Article

References (50)

1. Alessi M.C., Poggi M., and Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr. Opin. Lipidol. 18 3 (2007) 240-245
2. Axelsson S., Hagg S., Eriksson A.C., Lindahl T.L., and Whiss P.A. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 34 8 (2007) 775-780
3. Ayuso J.L., and Ruiz J.S. Neuroleptic-induced antinuclear antibodies. Eur. Psychiatry 11 7 (1996) 378-379
4. Baptista T., and Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?. Can. J. Psychiatry 47 8 (2002) 742-749
5. Baptista T., Dávila A., El Fakih Y., Uzcátegui E., Rangel N., Olivares Y., Galeazzi T., Vargas D., Peña R., Marquina D., Villarroel V., Teneud L., and Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and body mass index before and after olanzapine treatment in schizophrenia. Int. Clin. Psychopharmacol. 22 4 (2007) ̈205-̈211
6. Chang M., Binder C., Torzewski M., and Witztum J. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. U. S. A. 99 20 (2002) 13043-13048
7. Colwell J.A. Treatment for the procoagulant state in type 2 diabetes. Endocrinol. Clin. North Am. 30 4 (2001) 1011-1029
8. Danesh J., Wheeler J., and Hirschfield G. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New. Engl. J. Med. 350 14 (2004) 1387-1397
9. Davis S., Kern H.B., and Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am. J. Hematol. 46 2 (1994) 166-167
10. De Taeye B., Smith L.H., and Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr. Opin. Pharmacol. 5 2 (2005) 149-154
11. Dickerson F., Stallings C., Origoni A., Boronow J., and Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 93 1-3 (2007) 261-265
12. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., and Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149 1-3 (2007) 267-271
13. Festa A., D'Agostino Jr. R., Mykkanen L., Tracy R.P., Zaccaro D.J., Hales C.N., and Haffner S.M. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol. 19 3 (1999) 562-568
14. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 1 (2000) 42-47
15. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 51 4 (2002) 1131-1137
16. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders. Research Version, Patient Edition, Version 2.0. (SCID/P) (1996), New York Psychiatric State Institute, Biometrics Research, New York
17. Fonseca V., and Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. Am. J. Cardiol. 92 12B (2005) 13M-18M
18. Grieninger G., Plant P.W., Liang T.J., Kalb R.G., Amrani D., Mosesson M.V., Hertzberg K.M., and Pindyc J. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann. N. Y. Acad. Sci. 408 (1983) 469-499
19. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular diseases. Am. J. Cardiol. 97 2A (2006) 3A-11A
20. Hagg S., and Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 16 11 (2002) 765-773
21. Hagg S., Tatting P., and Spigset O. Olanzapine and venous thromoembolism. Int. Clin. Psychohamacol. 18 5 (2003) 299-300
22. Haupt D.W., Luber A., Maeda J., Melson A.K., Schweiger J.A., and Newcomer J.W. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacol 30 1 (2005) 184-191
23. Kudoh A., Sakai T., Ishihara H., and Matsuki A. Plasma cytokine response to surgical stress in schizophrenic patients. Clin. Exp. Immunol. 125 1 (2001) 89-93
24. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
25. Liperoti R., Pedone C., Lapane K.L., Mor V., Bernabei R., and Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch. Intern. Med. 165 22 (2005) 2677-2682
26. Mazzarello V., Cecchini A., Fenu G., Rassu M., Dessy L.A., Lorettu L., and Montella A. Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Ital. J. Anat. Embryol. 109 3 (2004) 177-188
27. Metzer W.S., Canoso R.T., and Newton J.E.O. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South. Med. J. 87 2 (1994) 190-192
28. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry 58 Suppl 10 (1997) 45-49
29. Newcomer J. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67 Suppl 9 (2006) 25-30
30. Newcomer J. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1 (2007) 20-27
31. Nieuwdorp M., Stroes E.S.G., Meijers J.C.M., and Büller H. Hypercoagulability in the metabolic syndrome. Curr. Opin. Pharmacol. 5 2 (2005) 155-159
32. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gomez-Reino J.J., and Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579 2 (2005) 295-301
33. Parkin L., Skegg D., Herbison P., and Charlotte P. Psychotropic drug and fatal pulmonary embolism. Pharmacoepidemiol. Drug Saf. 12 8 (2003) 647-652
34. Pearson T., Mensah G., Alexander R., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., smith S.C., Taubert K.L., Tracy R.P., and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 3 (2003) 499-511
35. Pepys M., and Hirschfield G. C-reactive protein: a critical update. J. Clin. Invest. 111 12 (2003) 1805-1812
36. Quinsey N.S., Greedy A.L., Bottomley S.P., Whisstock J.C., and Pike R.N. Antithrombin: in control of coagulation. Int. J. Biochem. Cell Biol. 36 3 (2004) 386-389
37. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47 4 (2005) 201-210
38. Sarandol A., Kirli S., Akkaya C., Ocak N., Eroz E., and Sarandol E. Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. J. Psychopharmacol. 21 8 (2007) 857-863
39. Schwartz M., Rochas M., Weller B., Sheinkamn A., Tal I., Golan D., Toubi N., Eldar I., Sharf B., and Attias D. High association of anticardiolipin antibodies with psychosis. J. Clin. Psychiatry 59 1 (1998) 20-23
40. Shcherbakova I.V., Kaleda V.G., Barkhatova A.N., and Kliushnik T.P. Markers of endothelial dysfunction in attack-like schizophrenia. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. 105 3 (2005) 43-46
41. Söderberg S., Olsson T., Eliasson M., Johnson O., Hallmans G., Asplund K., and Olsson T. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J. Intern. Med. 245 4 (1999) 533-543
42. Tall A. C-reactive protein reassessed. N. Engl. J. Med. 350 14 (2006) 1450-1452
43. The IDF consensus worldwide definition of the metabolic syndrome (2007). http://www.idf.org Accessed Dec 21
44. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 106 25 (2002) 3143-3421
45. Toki S., Morinobu S., Yoshino A., and Yamawaki S.A. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. J. Clin. Psychiatry 65 11 (2004) 1576-1577
46. Walker A.M., Lanza L.L., Arellano F., and Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 8 6 (1997) 671-677
47. Weisberg S., McCann D., Desai M., Rosembaum M., Leibel R., and Ferante A. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 12 (2003) 1796-1808
48. Wolstein J., Grohmann R., Ruther E., and Hippius H. Association of venous thromboembolism and clozapine. Lancet 356 (2000) 252
49. Zimmet P., Magliano D., Matsuwa Y., Alberti G., and Shaw J. The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 12 6 (2005) 295-300
50. Zornberg G.L., and Jick H. Antipsychotic drug use and risk of first time idiopathic venous thromboembolism: a case-control study. Lancet 356 9237 (2002) 1219-1223